The city of Houston, Texas, currently has 589 active clinical trials seeking participants for Cancer research studies.
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Recruiting
This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Houston Methodist Urology Associates, Texas Medical Center, Houston, Texas
Conditions: Prostate Cancer
EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Recruiting
Open-label multicenter study
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: MD Anderson, Houston, Texas
Conditions: Colorectal Cancer Metastatic
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Recruiting
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
Recruiting
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastrostomy, Gastric, GastroEsophageal Cancer
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
Recruiting
The investigators are conducting this study with men that have prostate cancer and are getting standard of care treatment with the drugs abiraterone acetate and prednisone. The study will follow men with prostate cancer from initiation of participation in the study and for up to 10 years. The reason for the study is that researchers think that there may be a connection between the race and ethnicity of men with prostate cancer and how well the standard treatments work for the participants.
Gender:
Male
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: Ben Taub General Hospital, Houston, Texas +2 locations
Conditions: Prostate Cancer Metastatic, Prostate Cancer
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
Recruiting
This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Pancreatic Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Recruiting
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to t... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
10/04/2023
Locations: : The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Non-small Cell Lung Cancer
Informational Meetings for Planning and Coordinating Treatment
Recruiting
This prospective cluster-randomized trial examines the efficacy of a novel communication intervention delivered by trained physician and nurse dyads to parents of children with cancer within the clinicians' practice, to foster alignment of the goals of treatment. The investigators hypothesize that goal alignment will improve quality of life outcomes, in particular for those patients who reach end of life. Findings from the proposed research will provide essential information to promote communica... Read More
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
10/01/2023
Locations: MD Anderson Children's Cancer Center, Houston, Texas
Conditions: End of Life, Communication, Cancer Metastatic
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Recruiting
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Gender:
All
Ages:
Between 0 years and 30 years
Trial Updated:
09/30/2023
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Hepatocellular Carcinoma, Childhood, Liver Cancer, Fibrolamellar Carcinoma, Liver Cancer, Pediatric
TRUDI: TDXD+Durva in HER2+/Low IBC
Recruiting
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: Trastuzumab deruxtecan Durvalumab
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/28/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
Recruiting
To develop a shared decision-making (SDM) tool to help Spanish-speaking patients make decisions about their maintenance therapy
Gender:
All
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Recruiting
This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/25/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer